Upcoming Webinars

Join us for the upcoming webinar! Our Growth Director, George Hawwa, will present a deep dive into the recent algorithm changes on Meta and LinkedIn on September 24 at 11 AM.Don't miss out on this opportunity to learn how the algorithm works and how these changes can affect your content and your campaigns.Grab your virtual seat, and let's navigate these updates side by side.REGISTER NOW!

Intense operations must rigorously prioritize safety – including in their materials handling functions. In fact, improper forklift operation is one of the most common sources of citations from the Occupational Safety and Health Administration (OSHA) for many demanding, fast-paced industries like manufacturing, metals and paper.In this virtual event, an environmental health and safety (EHS) manager and a training expert from Hyster will discuss ways to assess and support materials handling best practices, including:Focus areas and safety culture indicators to evaluate within your facility or job siteHow to comply with OSHA requirements for lift truck operator trainingMethods to support better training engagement and knowledge retention

Invest in Australia's First Accredited Cosmetic Clinic.We are pleased to announce the Offer for the IPO of Stormeur Ltd (ASX:STR), parent company of Cosmetique, is now open. Join Jane Morgan, Investor and Media Relations Manager and Vivek Eranki (Chairman) for a Company overview.Stormeur Ltd OverviewOperating as Cosmetique, Australia's first accredited cosmetic clinic, Stormeur Ltd has demonstrated remarkable success, including established a network of 17 clinics across five Australian states, offering high-quality, affordable cosmetic injectable treatments and laser hair removal services.Key Investment Highlights:• Rapidly expanding market: The Australian facial injectable market is projected to grow at a CAGR of 19.3% to reach USD 9.09 billion by 2030.• Proven business model: Cosmetique has provided over 300,000 treatments in the past year alone.• Strong growth strategy: Plans to open 4 new clinics in New South Wales and Victoria within 24 months of listing.• Industry-leading standards: First cosmetic injectables clinic in Australia to achieve NSQPCH accreditation.• Experienced management: Led by founder Dr. Vivek Eranki, with a track record of successful clinic rollouts.Offer closes 5:00pm (AWST) on 14 October 2024.

The Inflation Reduction Act and the resulting Medicare Part D price negotiations are shaping up to be the most far reaching of any event impacting pharma manufacturing in recent history.Although the first set of negotiated prices for selected drugs will not take effect until January 1, 2026, the immediate impact has been fast and furious — more than a dozen lawsuits have been filed by pharmaceutical companies, advocacy groups and the US Chamber of Commerce. Industry media is ablaze with discussions on how price negotiations will impact the pricing of non-selected same-class drugs and biosimilars, as well as future drug development in general.With the first-round negotiated prices for selected drugs to be made public on September 1, 2024, companies are preparing themselves for the second round of selections. This timely webinar will provide an update on:To-date information on the legal actions, existing price negotiations, and market reactionsDrugs likely to be selected for the second round and their same-class competitors who will be impactedThe changes and impact of out-of-pocket costs on enrolleesPrice negotiation benchmarking on selected drugs compared to net pricing on competitorsHow manufacturers should prepare for the overall impact to the industryPart D plan utilization managementRegister for this webinar today to understand the profound impact of the Inflation Reduction Act and Medicare Part D price negotiations on the pharmaceutical industry.Speakers: Mark McCoy, RPh, MBA - Director, Client Engagement Pricing Market Access and Reimbursement, ICON; Amith Shetty, PharmD, RPh - Senior Clinical & Market Access Specialist, ICON; Dr. Xin Zhao - Principal, Global Market Access, ICON.Who Should Attend?This webinar will benefit pharmaceutical and biotech professionals in the following areas:Market access/Marketing/Managed markets/Market researchReal world evidenceRegulatory affairsChannel marketingClinical researchCompetitive intelligenceGovernment affairsHealth economics and outcomes researchWhat You Will LearnAttendees will learn about:The ongoing legal challenges initiated by pharmaceutical companies and other stakeholders against the Inflation Reduction Act’s price negotiation provisionsDrugs likely to be targeted in the upcoming rounds of Medicare Part D price negotiationsThe impact of changes to enrollees and drug manufacturers around reductions in patient out-of-pocket costsThe future impact on Part D plan utilization management

Join Santie van Niekerk in an illuminating webinar dedicated to cultivating a culture of trust in the work environment. This session, led by an expert in organizational dynamics, will delve into the critical elements that contribute to building trust among team members. Participants will gain practical insights into effective communication, transparent leadership, and fostering a collaborative atmosphere. Discover actionable strategies to create a workplace culture where trust thrives, promoting stronger teamwork, enhanced productivity, and a more positive organizational climate. Don't miss this opportunity to learn from Santie van Niekerk and transform your workplace into a trusting and collaborative space. NOTE: You will be given the opportunity to ask questions and clarify specific concerns with regards to topic presented.1. Follow this link to pre-register for the free webinar – 20 September 20242. After registering, you will receive a confirmation email containing information about joining the webinarSpeaker: Santie van Niekerk - Co-Founder & Director, MiChem Dynamics (PTY) Ltd.

Join us for an informative webinar tailored for healthcare providers interested in understanding and recommending serum tears to their patients. Serum tears, derived from a patient’s own blood, offer a natural and personalized treatment option for chronic dry eye and other ocular surface diseases.Our featured presenter, Dr. Matthew Ward, a leading expert in the industry, will guide you through the science behind serum tears, their therapeutic benefits, and the process of preparing and prescribing them.Dr. Ward will cover:• The benefits of serum tears and the compounding process• The cost-effectiveness of serum tears as a treatment option for patients• The safety of serum tears as opposed to traditional eye drops and solutions• And so much more!This session will equip you with the knowledge and tools to confidently recommend serum tears, offering your patients a cutting-edge solution to manage their eye health.Who Should Attend:• Ophthalmologists• Optometrists• Primary care physicians• Healthcare providers involved in ocular care

Are you looking to streamline your business operations and enhance efficiency? Join us for a comprehensive overview of Microsoft Dynamics 365 Business Central where we will explore how your organization can work faster, smarter and more collaboratively by:  Engaging your critical data through Office 365.Analyzing and presenting pertinent and timely information.Accessing information from anywhere.Leveraging Microsoft Copilot to work for you.Whether you’re a small business or a large enterprise, we’ll provide you with knowledge and strategies to harness the full potential of Microsoft Dynamics 365 Business Central.Join Dane Koepke and Umair Mehmood on Thursday, September 19, at 1 p.m. ET/12 p.m. CT and learn how to transform your financial operations.

TeachTown will be hosting a Virtual Summit for special educators on 9/19 from 11 am ET - 1 pm ET. As you kick off the 24-25 school year, this Virtual Summit has been designed to walk you through best practices for:• Classroom Management• Outcomes/Data• Instructional Methodologies • K-12 Standards-First, Adapted CurriculumIf you can’t attend the full duration of the summit, don’t stress! You can pop in and out of sessions as your schedule allows - and of course, all registrants will receive a replay link following the event.

Join us for this webinar and hear from S&P Global Commodity Insights experts explore the current state and development of carbon markets—both voluntary and compliance—worldwide. We will cover aspects such as the infrastructure, monitoring and verification of emissions, market fundamentals, and price trends. We will draw on interesting case studies to highlight key developments ahead of COP 29.Agenda at a GlanceWelcome & introduction.Hear from our panel on what they currently see in Carbon markets.   The state of Carbon markets in 2024 – where are we now?Focus on the global landscape: country progress, regulatory developments, market infrastructure, measurement (monitoring and verification) of emissions, market fundamentals, and price trends. Also, the role of technology and how it is evolving.   Opportunities, challenges, and the road to COP29.Focus on what is needed to strengthen and evolve markets; provide examples of innovative aspects we are seeing around the world; discuss expectations for COP29 and the likelihood of progress on key aspects that will shape Carbon markets, notably Article 6.   Expectations for 2025.Where do we think Carbon markets will be a year from now? What do we want to see vs what is likely? Q&ASpeakers: Roman Kramarchuk, Head – Climate Markets and Policy Analytics, S&P Global Commodity Insights; Jonty Rushforth, Head of Environmental Solution, S&P Global Commodity Insights; Deb Ryan, Head of Emissions Insight, S&P Global Commodity Insights; Marie-Louise du Bois, Global Head of Carbon Pricing, S&P Global Commodity Insights.

There has never been a more exciting and promising time in pharmacological research related to obesity drugs. It is now broadly accepted that obesity is not just a lack of willpower but a complex chronic disease with increased morbidity and mortality that can be managed with the right treatment.Over the past decade or so, gut hormone-based drug development targeting obesity and type 2 diabetes indications and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) as dual or triple agonists or other complementary mode of action have increased rapidly.Semaglutide and, most recently, tirzepatide have demonstrated that a two-digit weight loss at one year is achievable and the Phase II data with retatrutide suggest that 100 percent of patients can now achieve the 5 percent weight loss that was targeted in the past. The next stage in obesity research needs to bring affordable and accessible drugs that can lead to selective fat loss, preservation of lean body mass and long-term weight maintenance. As with many other chronic diseases, combination therapies with complementary modes of action will be required to successfully treat patients with obesity.The objective of this webinar is to discuss the potential next steps in pharmacotherapy targeting obesity. The expert speakers will initially focus on the size of the health burden, the history of drug development and the current pipeline in this indication. They will also focus on the current methodologies to assess body composition. They will discuss the potential additional targets, beyond energy intake, to complement and improve the quality of weight loss and its maintenance, as well as present the methodologies that can be used to assess different components of energy expenditure (EE) and explain the concept of metabolic adaptation and the potential physio-pathological mechanisms involved.Moreover, they will discuss the implications of the changes in EE and metabolic adaptation in long-term weight maintenance. Finally, they will focus on brain imaging and how it can help to understand eating behavior and neurocognitive measures in obesity. The webinar will conclude with the current challenges and mitigation strategies for future clinical trials in obesity.Register for this webinar today to understand the latest advancements related to obesity pharmacotherapy.Speakers: Dr. Eric Ravussin, PhD - Boyd Professor, Douglas L. Gordon Chair in Diabetes and Metabolism, Pennington Biomedical Research Center-LSU System, Baton Rouge, Louisiana; Dr. Claudia Filozof - Vice President and Therapeutic Area Head in Obesity, MASH and Liver Indications, Fortrea; Dr. Peter Alfinito, PhD - Executive Director, Operational Strategy & Planning, Fortrea.Who Should Attend?This webinar is designed for drug developers, healthcare professionals, patient advocacy groups and anyone interested in the advancement of obesity drug development.What You Will LearnAttendees will learn about:Understanding obesity’s health burden and the evolution of drug development in obesityMethodologies used to evaluate body composition in the context of obesity researchPotential additional targets beyond energy intake to enhance weight loss quality and maintenanceCurrent challenges in obesity clinical trials and strategies to mitigate these challenges for future research efforts